These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 19997926

  • 1. Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection.
    Roh MI, Lim SJ, Ahn JM, Lim JB, Kwon OW.
    Graefes Arch Clin Exp Ophthalmol; 2010 May; 248(5):635-40. PubMed ID: 19997926
    [Abstract] [Full Text] [Related]

  • 2. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment.
    Roh MI, Kim HS, Song JH, Lim JB, Koh HJ, Kwon OW.
    Retina; 2009 Apr; 29(4):523-9. PubMed ID: 19262441
    [Abstract] [Full Text] [Related]

  • 3. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
    Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M.
    Retina; 2010 Apr; 30(7):1034-8. PubMed ID: 20616682
    [Abstract] [Full Text] [Related]

  • 4. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF, Sánchez JG, Wu L, Berrocal MH, Alezzandrini AA, Restrepo N, Maia M, Farah ME, Brito M, Díaz-Llopis M, Rodríguez FJ, Reategui G, Iturralde-Iraola J, Udaondo-Mirete P, Pan-American Collaborative Retina Study Group.
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 9. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
    Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS, Pang CP.
    Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
    Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA, Scott IU.
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454
    [Abstract] [Full Text] [Related]

  • 12. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration.
    Ahn JK, Moon HJ.
    Am J Ophthalmol; 2009 Nov; 148(5):718-724.e1. PubMed ID: 19674731
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 Nov; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 16. Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
    Byun YJ, Lee SJ, Koh HJ.
    Jpn J Ophthalmol; 2010 Nov; 54(6):571-7. PubMed ID: 21191718
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study.
    Bashshur ZF, Haddad ZA, Schakal AR, Jaafar RF, Saad A, Noureddin BN.
    Am J Ophthalmol; 2009 Jul; 148(1):59-65.e1. PubMed ID: 19375689
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
    Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA.
    Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
    [Abstract] [Full Text] [Related]

  • 20. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
    Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM.
    Retina; 2006 May; 26(9):994-8. PubMed ID: 17151485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.